Compugen Ltd.
A clinical-stage company developing cancer immunotherapies using an AI platform.
CGEN | TA
Overview
Corporate Details
- ISIN(s):
- IL0010852080
- LEI:
- Country:
- Israel
- Address:
- 26 Harokmim St., Bldg D, 5885849 Holon
- Website:
- https://www.cgen.com/
Description
Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in cancer immunotherapy. A pioneer in its field, the company leverages a proprietary, broadly applicable, and predictive AI-powered computational discovery platform to identify novel drug targets. Its primary focus is on developing innovative, first-in-class therapeutics designed to modulate the tumor microenvironment and enhance anti-tumor immune responses. Compugen's mission is to advance its pipeline of drug candidates to address patient populations unresponsive to current immunotherapy treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-08-05 15:59 |
annual general meeting of shareholders to be held on September 12, 2024
|
English | 291.4 KB | ||
| 2024-08-05 15:59 |
annual general meeting of shareholders to be held on September 12, 2024
|
English | 160.0 KB | ||
| 2024-07-29 15:59 |
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid T…
|
English | 79.0 KB | ||
| 2024-07-29 15:59 |
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid T…
|
English | 36.3 KB | ||
| 2024-07-23 15:59 |
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024, con…
|
English | 88.9 KB | ||
| 2024-07-23 15:59 |
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024, con…
|
English | 36.3 KB | ||
| 2024-06-17 15:59 |
Compugen to Present at Upcoming Antibody Industrial Symposium
|
English | 143.6 KB | ||
| 2024-06-17 15:59 |
Compugen to Present at Upcoming Antibody Industrial Symposium
|
English | 36.2 KB | ||
| 2024-05-30 15:59 |
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in t…
|
English | 141.9 KB | ||
| 2024-05-30 15:59 |
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in t…
|
English | 36.4 KB | ||
| 2024-05-20 15:59 |
Reports First Quarter 2024 Results
|
English | 488.2 KB | ||
| 2024-05-20 15:59 |
Reports First Quarter 2024 Results
|
English | 36.2 KB | ||
| 2024-05-16 15:59 |
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVR…
|
English | 113.2 KB | ||
| 2024-05-16 15:59 |
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVR…
|
English | 36.3 KB | ||
| 2024-05-15 15:59 |
Compugen Appoints David Silberman as Chief Financial Officer
|
English | 473.0 KB |
Automate Your Workflow. Get a real-time feed of all Compugen Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Compugen Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Compugen Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
